Radiotherapy/Radiation / NLR Cancer Research Results

Rad, Radiotherapy/Radiation: Click to Expand ⟱
Features:
Treatment of disease with radiation, especially by selective irradiation with x-rays or other ionizing radiation and by ingestion of radioisotopes.

Radiosensitizer
Atorvaqone, (mitochondria inhibitor) decrease O2 consumption making more O2 available as a radiosensitizer.
-Hypoxia (low oxygen levels) within tumors is a major cause of resistance to radiotherapy


NLR, neutrophil-to-lymphocyte ratio (NLR): Click to Expand ⟱
Source:
Type: BioMarker

Neutrophil-to-lymphocyte ratio (NLR) is a calculated blood-based inflammatory biomarker obtained by dividing the absolute neutrophil count by the absolute lymphocyte count. It reflects the balance between systemic inflammation, represented partly by neutrophils, and lymphocyte-mediated immune activity.

In cancer, an elevated NLR is frequently associated with greater inflammatory burden, impaired antitumour immunity, more advanced disease, poorer treatment response, and reduced progression-free or overall survival. A decreased NLR is therefore generally considered the favourable direction, although its meaning depends on cancer type, disease stage, treatment, and the timing of measurement.

NLR is a nonspecific biomarker and may be altered by infection, corticosteroids, chemotherapy, granulocyte colony-stimulating factors, bone-marrow suppression, smoking, stress, and other inflammatory or medical conditions. There is no single universal cutoff value; thresholds commonly vary between approximately 3 and 5 across studies.

Calculation: absolute neutrophil count divided by absolute lymphocyte count.

Generally favourable cancer direction: decreased NLR. NLR should be classified as a hematologic biomarker or inflammatory index rather than as a direct molecular target.



Scientific Papers found: Click to Expand⟱
7481- H2,  Rad,    Clinical Efficacy of Hydrogen Therapy on Acute Radiation Enteritis and Inflammatory Response in Patients with Cervical Cancer Undergoing Concurrent Chemoradiation Therapy
- Trial, Var, NA
Dose↝, CRP↓, NLR↓, IL6↓, AntiTum∅, *toxicity↓, Inflam↓, radioP↑, *IBI↑, *ROS↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NLR↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CRP↓, 1,   IL6↓, 1,   Inflam↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

CRP↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum∅, 1,   radioP↑, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↓, 1,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,  

Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,  
Total Targets: 3

Scientific Paper Hit Count for: NLR, neutrophil-to-lymphocyte ratio (NLR)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:201  Target#:1527  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page